Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study.
Susanna HallbergBjörn EvertssonEllen LillvallMalin BoremalmPierre de FlonYunzhang WangJonatan SalzerJan N LyckeKatharina FinkThomas FrisellFaiez Al NimerAnders SvenningssonPublished in: European journal of neurology (2024)
Accumulated dose and time on rituximab treatment are associated with a modest but significant decline in immunoglobulin levels. Previous MS therapies may influence additional IgG decline.